Prospect Bio

company

About

Prospect Bio is a synthetic biology company that specializes in building biosensors (living cells) that can measure chemicals.

  • 11 - 50

Details

Last Funding Type
Seed
Last Funding Money Raised
$2.80M
Industries
Bioinformatics,Biotechnology,Neuroscience
Founded date
Jan 1, 2013
Number Of Employee
11 - 50
Operating Status
Active

Prospect Bio is a synthetic biology company that specializes in building biosensors (living cells) that can measure chemicals. Biosensors are powerful measurement tools which can perform highly complex testing tasks while being near costless to manufacture, field deployable, and massively scalable. As such, Prospect's work generally focusses on taking broken testing processes - often ones that rely on expensive ($0.5M+), slow, and lab-bound equipment - and replacing them with an affordable, scalable, and on-site biosensor based solutions. The need for improved testing solutions is being driven on a variety of fronts, including growing regulation, increased QC, and concerns about supply chain assurance. This problem set affects numerous industries, as shown by Prospect's diverse partner list which includes one of the three largest wine companies in the the world, a leading California-based Ag company, a prenatal diagnostics maker, and Ginkgo Bioworks.

Prospect Bio has raised $2.8M, and is supported by investors including Illumina, Viking Capital, Stanford-StartX, Digital Sky Technologies, and Rising Tide Fund.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$2.80M
Prospect Bio has raised a total of $2.80M in funding over 2 rounds. Their latest funding was raised on Nov 15, 2016 from a Seed round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 15, 2016 Seed $2.80M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Prospect Bio is funded by 1 investors. Think + Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Think + Ventures Seed